Exenatide (Byetta, Bydureon)
Exenatide (synthetic exendin-4)
FDA-approved GLP-1 receptor agonist for type 2 diabetes, derived from Gila monster venom peptide exendin-4, with consistent evidence for weight reduction and emerging but mixed results in Parkinson's disease (Phase 2 positive, Phase 3 negative), PCOS, and alcohol use disorder (PMID 28781108; PMID 20332357;).
Last updated: 2026-03-10
Safety Summary
GI adverse effects are the most commonly reported and are typically transient, resolving within the first 4-8 weeks of treatment. In the FDA label, nausea occurred in up to 44% of patients on combination therapy (18% placebo), vomiting in 13% (4% placebo), diarrhea in 13% (6% placebo). In the AUD trial (PMID 36066977), nausea was 37.1% vs 15.4% placebo, vomiting 22.6% vs 7.7%, and injection site reactions 41.0% vs 0.0%. Injection site reactions with Bydureon typically present as small (1-2 cm), hard, mobile, skin-colored nodules that resorb within 6 weeks (PMID 36066977). In the inpatient trial (PMID 30679302), nausea/vomiting occurred in 10-11% of exenatide-treated groups vs 2% in basal-bolus insulin group. No pancreatitis events were reported across the filtered studies. Anti-exenatide antibodies develop in approximately 38-63% of patients depending on formulation and study, but in most patients do not correlate with reduced efficacy (PMID 36066977;). Drug-induced immune-mediated thrombocytopenia is a postmarketing finding with potentially fatal bleeding. Weight loss is a consistent pharmacological effect rather than adverse effect.
Known Side Effects
common
common
common
common
common
common
common
common
common
uncommon
uncommon
uncommon
rare
rare
rare
rare
rare
rare
Who Should NOT Use This
Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported. Contraindicated per FDA label.
Serious bleeding, which may be fatal, has been reported. Rechallenge must be avoided.
Bydureon (extended-release) carried a boxed warning: GLP-1 receptor agonists cause thyroid C-cell tumors in rodents at clinically relevant exposures. This warning applied to extended-release formulations. The current Byetta label does not carry this boxed warning, but the risk applies to the exenatide molecule in extended-release context.
Due to the thyroid C-cell tumor risk with extended-release formulations, contraindicated in patients with MEN 2.
Acute pancreatitis including fatal hemorrhagic and necrotizing pancreatitis has been observed with GLP-1 receptor agonists including exenatide. Discontinue if pancreatitis is suspected.
Exenatide is renally cleared. Not recommended in patients with severe renal impairment or receiving dialysis due to risk of accumulation and worsening renal function. Use with caution in renal transplant patients.
Exenatide is not a substitute for insulin and should not be used in type 1 diabetes or for treatment of diabetic ketoacidosis. Note: adjunctive use in T1D has been studied investigationally (PMID 20332358).
Increased risk of hypoglycemia when used with sulfonylureas or insulin. Dose reduction of the secretagogue or insulin may be needed.
Exenatide delays gastric emptying and is not recommended in patients with severe gastrointestinal disease or gastroparesis.
Because exenatide slows gastric emptying, the FDA label recommends timing oral drugs that need rapid absorption with caution.
Talk to Your Doctor
Before considering Exenatide (Byetta, Bydureon), discuss it with your healthcare provider. Ask about potential interactions with your current medications, whether it is appropriate for your health conditions, and what monitoring may be needed.
Sources: [1-21]
Evidence Assessment
Exenatide has full FDA approval for type 2 diabetes in both adults (since 2005) and pediatric patients aged 10-17 (since 2021), supported by multiple Phase 3 randomized controlled trials. The original registration trial (NCT00082381, N=733), DURATION-NEO-2 (N=365, PMID 28205322), and the pediatric T2D trial (N=83, PMID 35679098) are representative Phase 3 studies. Tier 1 is appropriate for adult type 2 diabetes. For non-diabetic indications: Parkinson's disease neuroprotection is now at Tier 4-5 (Phase 2 positive but Phase 3 negative), PCOS is at Tier 3 (small RCTs), and alcohol use disorder is at Tier 4-5 (Phase 2 negative primary endpoint, PMID 36066977).
1Effects of Exenatide Compared to Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Oral Antidiabetic AgentsNCT00082381
Amylin Pharmaceuticals (registration-supporting trial) - ClinicalTrials.gov (registration-era study) (2004) - Registration-supporting randomized placebo-controlled trial - N=733
At week 30, HbA1c changed by -0.86% with exenatide 5 mcg and -0.98% with exenatide 10 mcg versus -0.12% to -0.13% with placebo. Body weight fell by -1.6 kg and -2.8 kg with exenatide versus small gains with placebo.
Limitations: Older registration-era study using immediate-release exenatide and background therapies that are no longer the modern standard of care.
2Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trialNCT01971242PMID 28781108
Athauda D et al. - Lancet (2017) - Phase 2 RCT - N=62 (32 exenatide, 30 placebo)
Exenatide 2 mg QW showed a 3.5-point advantage on MDS-UPDRS motor subscale (part 3) vs placebo at 60 weeks (48 weeks treatment + 12 weeks washout; adjusted difference -3.5, 95% CI -6.7 to -0.3, p=0.0318). CSF exenatide levels confirmed CNS penetration (11.4-11.7 pg/mL). Exenatide group lost 2.6 kg. IMPORTANT: The subsequent Phase 3 Exenatide-PD3 trial (2025) found no benefits over placebo.
Limitations: Small sample size (N=62). Single-center. Phase 3 did NOT replicate this finding. DaTscan changes may reflect pharmacological effect rather than disease modification.
3Once-Weekly Exenatide in Youth With Type 2 DiabetesNCT01779362PMID 35679098
Tamborlane WV et al. - Diabetes Care (2022) - Phase 3 RCT - N=83 (59 exenatide, 24 placebo)
HbA1c change: -0.36% exenatide vs +0.49% placebo. Between-group difference -0.85% (95% CI -1.51 to -0.19, p=0.012) at 24 weeks. This trial supported FDA approval of exenatide ER for pediatric T2DM (ages 10-17).
Limitations: Small sample size for a Phase 3 trial. Short duration (24 weeks). 3:1 randomization ratio limited placebo group size.
4Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: the DURATION-NEO-2 randomized clinical trialNCT01652729PMID 28205322
Wysham CH et al. - Diabetes Obesity and Metabolism (2017) - Phase 3 RCT - N=365 (181 exenatide QWS-AI, 122 sitagliptin, 61 placebo; 3:2:1 ratio)
HbA1c reduction at 28 weeks: exenatide -1.13% vs sitagliptin -0.75% (LSM difference -0.38%, p=0.021) vs placebo -0.40% (LSM difference -0.72%, p=0.001). Proportion achieving HbA1c <7.0%: 43.1% exenatide vs 32.0% sitagliptin vs 24.6% placebo. Body weight decreased similarly with exenatide (-1.1 kg) and sitagliptin (-1.2 kg). Steady-state plasma concentrations achieved by weeks 6-7.
Limitations: Open-label design for the exenatide arm. 28-week duration. Weight loss lower than expected compared to previous exenatide QW studies.
5Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 DiabetesNCT03297879PMID 29358950
Wang W et al. - Journal of Diabetes Investigation (2018) - Prospective nonrandomized interventional study - N=230 enrolled (224 completed: 106 exenatide, 118 metformin)
HbA1c reduction at 12 weeks: -2.81% exenatide vs -1.44% metformin (p<0.01). HbA1c <7.0% achieved: 79.5% exenatide vs 64.0% metformin (p<0.05). Body weight loss: -5.79 kg exenatide. Exenatide treatment and baseline HbA1c were independent predictors of HbA1c reduction.
Limitations: Not randomized (patients chose treatment). Open-label. 12-week duration only. Single ethnic population (Chinese). After adjustment for weight loss, no significant difference in HbA1c reduction.
6Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trialNCT03232112PMID 36066977
Klausen MK et al. - Journal of Clinical Investigation Insight (2022) - RCT - N=127 (62 exenatide, 65 placebo)
Primary endpoint (heavy drinking days reduction) not met. fMRI showed significantly reduced alcohol cue reactivity in ventral striatum (p=0.037), dorsal striatum (p=0.019), and putamen (p=0.037). SPECT showed lower DAT availability in exenatide group. Exploratory: in obese patients (BMI>30, n=30), exenatide reduced heavy drinking days by 23.6 percentage points (p=0.034). GI side effects: nausea 37.1% vs 15.4%, vomiting 22.6% vs 7.7%. BMI reduction: -0.95 (p=0.006). 54.3% dropout rate.
Limitations: Did not meet primary endpoint. High dropout rate (54.3%). BMI subgroup finding was post-hoc/exploratory. fMRI and SPECT substudies had small sample sizes (n=22 and n=16).
7Exenatide has a Pronounced Effect on Energy Intake but not Energy Expenditure in Non-Diabetic Subjects with Obesity: a Randomized, Double-blind, Placebo-Controlled TrialNCT00856609PMID 26542264
Piaggi P et al. - Diabetes Obesity and Metabolism (2016) - RCT - N=80 (41 exenatide, 39 placebo)
Exenatide decreased ad libitum energy intake by 1016 +/- 724 kcal/day vs 245 +/- 711 kcal/day with placebo (difference -625 kcal/day, p<0.0001). Relative to WMEN: -367 vs -8 kcal/day (p=0.03). No effect on 24-hour energy expenditure or substrate oxidation. At 24 weeks, food intake difference waned.
Limitations: Small sample size. Vending machine paradigm may not reflect real-world eating. No titration period. Non-diabetic population.
8Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-DiabetesNCT00375492PMID 20332357
Elkind-Hirsch K et al. - Diabetes Care (2010) - RCT - N=152 (73 exenatide, 79 placebo)
Exenatide + lifestyle: -5.1 +/- 0.5 kg weight loss vs -1.6 +/- 0.5 kg with placebo (p<0.001). Placebo-subtracted weight loss: -3.3 +/- 0.5% (p<0.001). IGT/IFG normalized in 77% exenatide vs 56% placebo.
Limitations: 24-week duration. Non-diabetic obese population. Weight regain trajectory after discontinuation not assessed.
9A Randomized Controlled Trial on the Safety and Efficacy of Exenatide Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 DiabetesPMID 30679302
Umpierrez GE et al. - Diabetes Care (2019) - Open-label RCT - N=150 (50 per group: exenatide alone, exenatide + basal insulin, basal-bolus insulin)
Mean daily BG: exenatide+basal 154 +/- 39 mg/dL similar to basal-bolus 166 +/- 40 mg/dL (p=0.31). Exenatide+basal achieved highest proportion BG 70-180 mg/dL (78% vs 62% vs 63%, p=0.023). No differences in hypoglycemia <54 mg/dL.
Limitations: Open-label design. Pilot study with moderate sample size. Hospitalized population with heterogeneous conditions.
10Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndromeNCT04029272PMID 34732660
Liu X et al. - Medicine (2021) - Open-label RCT - N=50 (25 combination, 25 metformin alone); 40 completed
Exenatide QW + metformin superior to metformin alone: weight -3.8 vs -2.1 kg (p=0.045), BMI -1.4 vs -0.77 (p=0.041), waist circumference -4.63 vs -1.72 cm (p=0.023). Fasting glucose, OGTT 2-h glucose, and insulin significantly lower with combination.
Limitations: Small sample size. Short duration (12 weeks). 20% dropout rate. Single-center. Open-label. Concomitant Diane-35 use.
11Combined metformin and exenatide versus only metformin treatments in polycystic ovary syndrome with abdominal obesity and network pharmacology of gene expressionNCT04029272PMID 40843067
Li M et al. - Fertility and Sterility (2024) - RCT with network pharmacology - N=66 (35 combination, 31 metformin alone)
Both treatments reduced total testosterone, insulin, and lipoprotein levels. Both increased HDL-C and apolipoprotein A1. Network pharmacology identified 154 key PCOS genes regulated by the combination.
Limitations: Short duration (12 weeks). Network pharmacology is predictive, not validated experimentally. Small sample size.
12Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic controlNCT02794402PMID 38027106
Forslund A et al. - Pediatric Obesity (2023) - Sub-study of RCT (Combat-JUDO) - N=44 (19 treatment, 18 placebo completed)
Exenatide maintained endogenous total GLP-1 levels during OGTT (no suppression). Significantly lowered DPP-4, proinsulin, and proinsulin-to-insulin ratio at fasting. Increased glicentin levels.
Limitations: Small sample size. Sub-study of a larger trial. Per-protocol analysis.
13The Role of Adjunctive Exenatide Therapy in Pediatric Type 1 DiabetesPMID 20332358
Raman VS et al. - Diabetes Care (2010) - Double-blinded crossover RCT - N=8
Both doses of exenatide (1.25 and 2.5 mcg) significantly reduced postprandial glucose excursions over 300 minutes vs insulin monotherapy (p<0.0001). Exenatide delayed gastric emptying (p<0.004) but failed to suppress glucagon.
Limitations: Very small sample size (N=8). Short-term (single meal) assessment. Adolescent T1D population only.
14Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and MetforminPMID 20357372
Arnolds S et al. - Diabetes Care (2010) - Open-label RCT - N=48 (16 per arm)
Both exenatide and sitagliptin added to glargine + metformin significantly reduced 6-hour postprandial glucose excursion vs control (p=0.0036 and p=0.0008). A1C decreased most with triple therapy including exenatide (-1.9 +/- 0.7%) vs control (-1.2 +/- 0.5%; p=0.0154). Weight decreased with exenatide (-0.9 kg, p=0.04).
Limitations: Small sample size. Short duration (4 weeks). Open-label. Single-center.
15Acute Exenatide Therapy Attenuates Postprandial Vasodilation in Humans with Prediabetes: A Randomized Controlled TrialNCT02104739PMID 32228379
Preston TJ et al. - Physiological Reports (2020) - Randomized crossover trial - N=15
Exenatide attenuated resting forearm blood flow at 3 hours (p=0.003) and 6 hours (p=0.056) postmeal. Transient postprandial triglyceride increase was abated. Exenatide prevented postmeal glucose increase.
Limitations: Very small sample size (N=15). Acute single-dose study. Prediabetic population only.
16Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction (EXAMI): study protocol for a randomized controlled trialNCT01254123PMID 22067476
Scholte H et al. - Trials (2011) - Protocol paper (multicenter RCT) - Planned N=108
Protocol for evaluating IV exenatide (5 mcg bolus + 20 mcg/24h for 72h) on infarct size reduction in acute MI patients treated with primary PCI.
Limitations: Protocol paper only -- no results reported in this publication.
17Effects of Exenatide on Weight and Appetite in Overweight Adolescents and Young Adults with Prader-Willi SyndromePMID 27071367
Miller JL et al. - Journal of Pediatric Endocrinology and Metabolism (2016) - Open-label pilot study - N=10
Appetite scores decreased significantly after 6 months of exenatide (p=0.004). No significant change in body weight or BMI. HbA1c decreased. Well tolerated.
Limitations: Very small sample size. Open-label, no placebo control. 6-month duration. Single-center.
18The Changes of Lipidomic Profiles Reveal Therapeutic Effects of Exenatide in Patients With Type 2 DiabetesPMID 35432194
Chen X et al. - Frontiers in Endocrinology (2022) - Observational cohort with lipidomics - N=35 T2DM patients + 20 healthy controls
Exenatide significantly reduced elevated sphingomyelins (SM d18:1/18:0, d18:1/18:1), LPC 16:0, and LPE 18:0 after 12 weeks, accompanied by improvement in TC, LDL-C, ApoA-I, FCP, and HbA1c.
Limitations: Small sample size. No placebo control. Single-center. 12-week duration. Observational design.
19Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathyNCT00766857PMID 28526033
van Eyk HJ et al. - Cardiovascular Diabetology (2017) - Open-label RCT - N=26 T2DM patients + 10 controls
No changes in cardiac function (LVEF), perfusion, or oxidative metabolism after 26 weeks of exenatide or insulin glargine. T2DM patients had impaired myocardial perfusion during hyperemia (p<0.01) vs controls.
Limitations: Very small sample size. Open-label. Male-only cohort.
20Insulin Glargine is More Suitable Than Exenatide in Preventing Muscle Loss in Non-Obese Type 2 Diabetic Patients with NAFLDNCT02303730PMID 37524110
Li J et al. - Diabetes Metabolism and Obesity (2023) - Post-hoc analysis of RCT - N=76 (38 per group)
Psoas muscle area tended to decrease with exenatide (-149.09 mm2, p>0.05). In non-obese males, insulin glargine significantly increased PMA vs exenatide (560.64 mm2, p<0.05).
Limitations: Post-hoc analysis. Small subgroup sizes. 24-week duration. Exploratory endpoint.
21Exenatide as an adjunct to nicotine patch for smoking cessation and prevention of postcessation weight gain: study protocolNCT05610800PMID 37316311
Koo BK et al. - BMJ Open (2023) - Protocol paper (RCT) - Planned N=216
Protocol for evaluating exenatide 2 mg QW + nicotine patch vs placebo + nicotine patch for 14 weeks in smokers with prediabetes/overweight. Primary outcomes: 4-week continuous abstinence and weight change.
Limitations: Protocol paper only -- no results reported.